Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Word to the Wise About Intranasal Esketamine.

Literature DB >> 31109197

A Word to the Wise About Intranasal Esketamine.

Alan F Schatzberg¹.

Abstract

Entities: Chemical Disease

Keywords: Depression; Esketamine; Ketamine

Mesh：

Substances：

Year: 2019 PMID： 31109197 DOI： 10.1176/appi.ajp.2019.19040423

Source DB: PubMed Journal: Am J Psychiatry ISSN： 0002-953X Impact factor: 18.112

Keyword Cloud
Cited

× No keyword cloud information.

25 in total

1. Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Authors: William V Bobo; Patricio Riva-Posse; Fernando S Goes; Sagar V Parikh
Journal: Focus (Am Psychiatr Publ) Date: 2020-04-23

Review 2. Ketamine: Leading us into the future for development of antidepressants.

Authors: Flavia R Carreno; Daniel J Lodge; Alan Frazer
Journal: Behav Brain Res Date: 2020-02-02 Impact factor: 3.332

3. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.

Authors: Jordi Bonaventura; Juan L Gomez; Meghan L Carlton; Sherry Lam; Marta Sanchez-Soto; Patrick J Morris; Ruin Moaddel; Hye Jin Kang; Panos Zanos; Todd D Gould; Craig J Thomas; David R Sibley; Carlos A Zarate; Michael Michaelides
Journal: Mol Psychiatry Date: 2022-06-29 Impact factor: 15.992

4. Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series.

Authors: Hewa Artin; Sean Bentley; Eamonn Mehaffey; Fred X Liu; Kevin Sojourner; Andrew W Bismark; David Printz; Ellen E Lee; Brian Martis; Sharon De Peralta; Dewleen G Baker; Jyoti Mishra; Dhakshin Ramanathan
Journal: EClinicalMedicine Date: 2022-05-06

Review 5. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors: Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal: Behav Brain Res Date: 2020-02-13 Impact factor: 3.332

6. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.

Authors: Jennifer Swainson; Alexander McGirr; Pierre Blier; Elisa Brietzke; Stéphane Richard-Devantoy; Nisha Ravindran; Jean Blier; Serge Beaulieu; Benicio N Frey; Sidney H Kennedy; Roger S McIntyre; Roumen V Milev; Sagar V Parikh; Ayal Schaffer; Valerie H Taylor; Valérie Tourjman; Michael van Ameringen; Lakshmi N Yatham; Arun V Ravindran; Raymond W Lam
Journal: Can J Psychiatry Date: 2020-11-11 Impact factor: 4.356

A Word to the Wise About Intranasal Esketamine.

1. Next-Step Treatment Considerations for Patients With Treatment-Resistant Depression That Responds to Low-Dose Intravenous Ketamine.

Review 2. Ketamine: Leading us into the future for development of antidepressants.

3. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search.

4. Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case series.

Review 5. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

7. Conformational flexibility within the small domain of human serine racemase.

Review 8. "Novel Psychopharmacology for Depressive Disorders".

9. Predicting and Managing Treatment Non-Response in Posttraumatic Stress Disorder.

10. Mechanisms associated with the antidepressant-like effects of L-655,708.